Olive Diagnostics’ KG is a non-invasive, hands-free, AI-powered optical equipment that can be put on any toilet. According to the company, it can be used in any home or clinic around the world to precisely detect biomarkers for medical problems and diseases such as prostate, ovarian, & kidney malignancies; heart failure; dehydration; kidney stones; and urinary bladder inflammation.
According to Olive Diagnostics, KG can identify 3,100 compounds in urine, including RBCs, ketone, protein, and creatinine, as well as other urine parameters including color, pressure, volume, and frequency. KG estimates chemical concentrations using advanced algorithms, analyses & tracks acquired data and informs users of any changes or abnormalities using cloud-based AI technology.
Because of its constant monitoring, the business believes that KG can alert users to presymptomatic disorders, often weeks before symptoms appear, making the equipment a perfect tool for the elderly, where early diagnosis can improve quality of life and care.
The clinical study, which was conducted by TechnoSTAT, was aimed at evaluating the system’s potential to identify proteins present in urine in over 900 samples. In a single test designed to imitate the standard urine stick method, KG has a sensitivity value of 92.8 percent and a specificity grade of 95.5 percent. Urine sticks have a sensitivity value of 80% and a specificity rating of 95%, according to the National Institutes of Health in the United States.
According to Olive Diagnostics’ press announcement, the true benefit of KG is its ability to continuously monitor urinations. On simulating five regular urination, TechnoSTAT discovered that KG had a sensitivity value of 98.7 percent and a specificity score of 100 percent. As a result, according to the company, the device is not only capable of doing the tests passively with no user-behavior changes, but it is also more precise than urine sticks, which are the gold standard for home-based diagnostics.
The company has completed its ISO 13485 accreditation, allowing it to develop and sell this technology in the EU. In the United States, the device is likewise in the pre-submission phase with the FDA.